Q2 FY26 results: standalone PAT up 105% YoY, SCSPL regulatory matter flagged

Revenue Growth 20pctPat Growth 25pctEmphasis Of MatterResults View source PDF Explain this filing

SYSTMTXC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹161.13

prior close

₹161.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-2.3% vs market

Stockbroking & Allied peers, median of 35sector+0.2%-1.6% vs sector

On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 1.6 pts less than its Stockbroking & Allied peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.2

15m

-0.2

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3+0.9-2.3+0.2-1.6

Next day

-2.6+0.8-3.4+0.2-2.8

-6.8+0.7-7.6-0.3-6.6

-6.2+1.3-7.6-0.7-5.5

-4.1+0.5-4.7-0.6-3.6

-6.3+0.4-6.6-1.0-5.3

+2.1-1.5+3.6-2.0+4.1

15d

-3.2-2.4-0.7-1.4-1.8

-1.8-4.4+2.6-3.5+1.7

-32.9-7.2-25.7-9.1-23.9

-47.7-5.0-42.7-12.1-35.6

UpDownMarket · Nifty Microcap 250Sector · Stockbroking & Allied peers, median of 35Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Systematix Corporate Services posted strong Q2 FY26 standalone results. Total income rose 121 percent to Rs 39.97 cr from Rs 18.11 cr YoY. Standalone PAT more than doubled to Rs 17.99 cr from Rs 8.78 cr. Consolidated PAT was Rs 14.48 cr against Rs 22.14 cr YoY. H1 FY26 consolidated PAT at Rs 24.94 cr. Auditor included an emphasis of matter on SEBI order cancelling subsidiary SCSPL's registration; matter sub judice with stay from SAT.

Likely market impact

Strong standalone show, but SEBI regulatory action on subsidiary SCSPL remains a key overhang for the stock.